Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC

Alexander Drilon, MD, a Chao-Hua Chiu, MD, b Yun Fan, MD, c Byoung Chul Cho, MD, PhD d Shun Lu, MD, PhD e Myung-Ju Ahn, MD, PhD f Matthew G. Krebs, MD, PhD g Stephen V. Liu, MD h Thomas John, MD i

*Corresponding author.

Disclosure: Dr. Drilon reports receiving consulting fees from ArcherDX, AbbVie, BergenBio, Hengrui Therapeutics, Blueprint Medicines, Ignyta/Genentech/F. Hoffmann-La Roche Ltd, AstraZeneca, MORE Health, Tyra Biosciences, Loxo/Bayesian Options, ZoLeb, Genomics, AXIS, Medscape, Liberman Med Learning, PeerView, EPG Health, INCCN/Harborside, Ology, Clinical Care Options, TouchMe, Entos, TreeLine, Prelude, and Applied Pharmaceutical Science, Inc.; honoraria from Helsinn, BeiGene, Remedica Ltd., TP Therapeutics, Verastem, Ignyta/Genentech/F. Hoffmann-La Roche Ltd, AstraZeneca, Liberman, Loxo-Bayer/Lilly, Lungevity, Lung Cancer Considered podcasts- RET, NIH, PER, OncLive, Clinical Care Options, Lung and Cancer Canada, AOIT, Chugai Pharm, Sirio Libanes Hospital, Answers in CME, Bayer-ECR, Faculty of More, and personalized Therapeutic Oncology Conference; receives royalties from Wolters Kluwer; participated in Data Safety Monitoring Boards or advisory boards for Takeda/Ariad/Mil- lenium, Exelixis, Monopletix, Ignyta/Genentech/F. Hoffmann-La Roche Ltd, AstraZeneca, EMD Serono, Meda, 14E/12/Evaluation Oncology, Novartis, Pfizer, Loxo/Bayer/Lilly, Repaire RX, Janssen, and Amgen; and other financial/nonfinancial interests in Merck, Puma, Merus, and Boehringer Ingelheim. Dr. Chiu reports receiving honoraria from Amgen, AstraZeneca/Medimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, F. Hoffmann-La Roche Ltd, and Takeda; advisory/consultancy for Bristol-Myers Squibb, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novar- its, and F. Hoffmann-La Roche Ltd. Dr. Fan reports receiving honoraria from Heng Rui Therapeutics, AstraZeneca, Bristol-Myers Squibb, Bei- Gene, Pfizer, Boehringer Ingelheim, and Sincere; and participated in a Data Safety Monitoring Board/advisory board for F. Hoffmann-La Roche Ltd. Dr. Cho reports advisory/consultancy for Novartis, AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, Merck Sharp & Dohme, Medpacto, Blueprint Medicines, InvitressBio Co. Ltd., Brigebio Therapeutics, CytoLabs Therapeutics, Guardant Health, Josep Bio; research grant/funding (institution) from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Jouleur, Yuhan, Ono/Pharmaceutical, Merck Sharp & Dohme, Medpacto, Gl Innovation, Elii Lilly, Blueprint Medicines, Interpark Bio Convergence Corp; stock ownership from TheraCanVoc Inc., Gencurix Inc., Bridgebio therapeutics, Kanaph Therapeutic Inc., CytoLabs Therapeutics, Interpark Bio Convergence Corp; licensing/royalties from Champions Oncology; is an officer/member of the board of directors for Genexir Inc., Interpark Bio Convergence Corp; and is a founder of DAAN Biotherapeutics. Dr. Shun Lu reports receiving consulting fees from AstraZeneca, Pfizer, Hutchinson MedPharma, ZoLeb, Genom- iCare, Yuhan Corporation, Menarini, InvitressBio Co. Ltd., and F. Hoffmann-La Roche Ltd; and honoraria from AstraZeneca, F. Hoffmann-La Roche Ltd, and Hansoh Pharma. Dr. Ahn reports honoraria from AstraZeneca, F. Hoffmann-La Roche Ltd, Merck Sharp & Dohme, Merck, Takeda, Ono Pharmaceutical, Novartis, Eli Lilly, Amgen, Yuhan, and Alphapharmaceutical. Dr. Krebs reports receiving honoraria from F. Hoffmann-La Roche Ltd; consulting/advi- sory fees from F. Hoffmann-La Roche Ltd, Guardant Health, Janssen, Seattle Genetics, OM Pharmaceutical Industries, Bayer; speakers’ bureau for F. Hoffmann-La Roche Ltd, Janssen, AstraZeneca; research funding from F. Hoffmann-La Roche Ltd, BergEnBio; and travel/ac- commodation/expenses from AstraZeneca, BergEnBio, and Immutrex. Dr. Liu reports receiving advisory/consultancy for Amgen, AstraZe- neca, F. Hoffmann-La Roche Ltd, Genentech, Janssen, Janssen; IQVIA; and research funding from F. Hoffmann-La Roche Ltd, Genentech, Merck, Merus, and Pfizer; research funding (to the institution) from AstraZeneca, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd/Genentech, Ignyta, and Merck; and participated in Data Safety Monitoring Boards for Novo- cure, and BeiGene. Dr. Tan reports receiving personal fees from Novartis, Bayer, Boehringer Ingelheim, AstraZeneca, Eli Lilly, LOXO Oncology, Merck, Pfizer, F. Hoffmann-La Roche Ltd, Takeda, and Mer- rimack; and grants from Novartis, Bayer, AstraZeneca, Pfizer, and GlaxoSmithKline. Dr. Patil received consulting fees from FCB Health; honoraria from AstraZeneca, Pfizer, Takeda, and Onclive; participated in Data Safety Monitoring Boards for Elevation Oncology; and participated in advisory boards for AstraZeneca, Pfizer, Takeda, Sanofi, Janssen, Mirati, and EMD Serono. Dr. Dzidauszko reports receiving advisory/consultancy for F. Hoffmann-La Roche Ltd, Foun- dation Medicine, Pfizer, AstraZeneca, Novartis, Merck Sharp & Dohme, Karyopharm, and Boehringer Ingelheim; honoraria from F. Hoffmann- La Roche Ltd, AstraZeneca, and Amgen; and participated in Data Safety Monitoring Boards/advisory boards for F. Hoffmann-La Roche Ltd, AstraZeneca, Amgen, and Merck Sharp & Dohme. Dr. Massarelli reports receiving consulting/advisory fees from Janssen, Eli Lilly, Bristol-Myers Squibb, Sanofi, Genentech, and Merck; and honoraria from AstraZeneca, Eli Lilly, Merck, and Takeda. Dr. Seto reports receiving honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Covidiem Japan, Daiichi Sankyo, Eli Lilly Japan, Kyowa Hakko Kirin, Merck Sharp & Dohme, Mochida Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Takeda Pharmaceutical, and Towa Pharmaceutical; research support from AbbVie, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, Merck Sharp & Dohme, Novartis Pharma, Pfizer Japan, Takeda Pharma- ceutical; and is an employee of Precision Medicine Asia. Dr. Doebele reports receiving consulting fees from Genentech/F. Hoffmann-La Roche Ltd, Ignyta, Pfizer, Takeda, AstraZeneca, Blueprint Medicines, Green Peptide, Anhian, Bayer, Guardant, Ariad, and Rain Therapeu- tics; support for attending meetings and/or traveling from F. Hoffmann-La Roche Ltd, Ignyta, and Blueprint Medicines; has patents planned, issued or pending from Abbott Molecular and Rain Therapeu- tics; has licensing/royalties from Takeda, Bristol-Myers Squibb, Thermo Fisher, Genentech, Black Diamond, Pearl River, Voronai, Scorpion Therapeutics, Foundation Medicine, Ignyta, Chugai, Blue- print Medicines, Abbott Molecular, and Rain Therapeutics; and is currently employed and is a shareholder of Rain Therapeutics. Ms. Pitcher is an employee of F. Hoffmann-La Roche Ltd. Drs. Kurikszkide and Heinzeim are employees of F. Hoffmann-La Roche Ltd. and hold shares in the company. Dr. Siena participated in advisory boards for AstraZeneca, Bayer, Bristol-Myers Squibb, Checkmate, Daiichi Sankyo, Guardant Health, Menarini, Merck, Novartis, F. Hoffmann-La Roche Ltd/Genentech, and Seattle Genetics.

Address for correspondence: Salvatore Siena, MD, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (La Statale), Ospedale Niguarda, Piazza Ospedale Maggiore 2, 20146 Milano, Italy. E-mail: salvatore.siena@unimi.it

Cite this article as: Drilon A, Chiu CH, Fan Y, et al. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC. JTO Clin Res Rep. 2022;3:100332. © 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

ISSN: 2666-3643

https://doi.org/10.1016/j.jtocrr.2022.100332
ABSTRACT

Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion–positive NSCLC with the central nervous system (CNS)–only progression post-crizotinib is reported.

Methods: Adults with ROS1 fusion–positive, locally advanced or metastatic NSCLC who received at least one dose of entrectinib and had 12 months or longer of follow-up were included in the analysis. Co-primary end points were confirmed objective response rate (ORR) and duration of response (DoR) by blinded independent central review. The data cutoff was on August 31, 2020.

Results: The efficacy-assessable population comprised 168 ROS1 TKI-naïve patients. The median survival follow-up was 29.1 months (interquartile range, 21.8–35.9). The ORR was 68% (95% confidence interval [CI]: 60.2–74.8); the median DoR was 20.5 months. The median progression-free survival (PFS) was 15.7 months and the median OS was 47.8 months. In the 25 patients with measurable baseline CNS metastases, the intracranial ORR was 80% (95% CI: 59.3–93.2), median intracranial DoR was 12.9 months, and median intracranial PFS was 8.8 months. Among 18 patients with CNS-only progression on previous crizotinib treatment, two achieved a partial response (11%) and four had stable disease (22%). In seven patients with measurable CNS disease from this cohort, the intracranial ORR was 14% (1 partial response).

Conclusions: Entrectinib is active and achieves prolonged survival in ROS1 TKI-naïve patients with ROS1 fusion–positive NSCLC. Modest activity is seen in patients with CNS-only progression post-crizotinib.

© 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Entrectinib; Intracranial efficacy; NSCLC; ROS1 fusions; Treatment post-crizotinib

Introduction

Gene rearrangements involving the tyrosine receptor kinase ROS1 can result in constitutively active fusion
oncoproteins.\textsuperscript{1,2} \textit{ROS1} fusions are found in a variety of tumor types, including 1\% to 2\% of NSCLC.\textsuperscript{1,3,4} Brain metastases are a common feature of \textit{ROS1} fusion–positive NSCLC, detected in up to 40\% of patients diagnosed with advanced disease.\textsuperscript{5–8}

Crizotinib was the first tyrosine kinase inhibitor (TKI) to be approved by the U.S. Food and Drug Administration as a first-line treatment for \textit{ROS1} fusion–positive NSCLC.\textsuperscript{9} However, crizotinib has limited ability to penetrate and remain in the central nervous system (CNS).\textsuperscript{10} In addition, the CNS is the first site of progression for approximately half of the patients with \textit{ROS1} fusion–positive NSCLC receiving crizotinib.\textsuperscript{7} Thus, newer targeted therapies for the treatment of \textit{ROS1} fusion–positive NSCLC must exhibit both overall and intracranial efficacy.

Entrectinib is a potent \textit{ROS1} TKI that was specifically selected for its ability to cross the blood–brain barrier and remain within the CNS.\textsuperscript{11–13} Results from an integrated analysis of three prospective, phase 1 or 2 clinical trials of entrectinib (ALKA-372-001: EudraCT 2012–000148–88; STARTRK-1: NCT02097810; STARTRK-2: NCT02568267) were previously published.\textsuperscript{14,15} In the efficacy-assessable population (N = 161; data cutoff May 2019), the objective response rate (ORR) was 67\% (95\% confidence interval [CI]: 59.3–74.3), with a median duration of response (DoR) of 15.7 months (95\% CI: 13.9–28.6) and a median progression-free survival (PFS) of 15.7 months (95\% CI: 11.0–21.1).\textsuperscript{15} Entrectinib also yielded durable intracranial responses in the subgroup of patients with baseline CNS metastases by blinded independent central review (BICR) (n = 46; intracranial ORR 52\%; median intracranial DoR 12.9 mo). In patients without baseline CNS metastases (by the investigator; n = 105), only three had confirmed new CNS lesions while on treatment.\textsuperscript{15} Entrectinib was well tolerated across the studies with a manageable safety profile.\textsuperscript{15}

Here, we report updated efficacy and safety findings from the integrated analysis of entrectinib in \textit{ROS1} fusion–positive NSCLC, with almost a doubling of the survival follow-up duration (median survival follow-up: 29.1 versus 15.8 mo in the previous analysis\textsuperscript{15}), the first estimation of median overall survival (OS), and additional patients. Furthermore, we provide the first published report of the activity of entrectinib in patients with intracranial-only progression post-crizotinib. Whereas the National Comprehensive Cancer Network (NCCN) guidelines recommend entrectinib as second-line therapy after progression on crizotinib, particularly for patients with CNS metastases,\textsuperscript{16} the activity of entrectinib in this population has not yet been reported. Finally, longitudinal changes in selected adverse effects such as the onset and improvement of neurologic and renal adverse effects are described.

Materials and Methods

Study Design and Patients

The full details of the three entrectinib studies included in our analysis (ALKA-372-001 and STARTRK-1 [phase 1]; STARTRK-2 [phase 2 global basket study]) have been published previously (study protocols are available online).\textsuperscript{14,17} Briefly, patients aged 18 years and older, with \textit{ROS1} fusion–positive, locally advanced or metastatic measurable NSCLC at baseline (locally assessed by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1\textsuperscript{18}) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 were enrolled into one of the three studies. The enrollment cutoff for this analysis was July 31, 2019 and the clinical cutoff was August 31, 2020: patients in the efficacy analysis had 12 months or longer of follow-up from the first post-treatment initiation scan (≥13 months from enrollment). Patients who discontinued the study or died before 12 months’ follow-up were also included.

In ALKA-372-001 and STARTRK-1, \textit{ROS1} gene fusions were identified by local testing using fluorescence in-situ hybridization, quantitative polymerase chain reaction, or DNA- and RNA-based next-generation sequencing. In STARTRK-2, additional tumor tissue was collected by means of local testing (unless a biopsy was contra-indicated) for independent next-generation sequencing. Patients with asymptomatic or pretreated and controlled CNS metastases were also eligible.

This analysis comprised data from two non-overlapping patient cohorts: a \textit{ROS1} TKI–naïve cohort from the integrated analysis of entrectinib (N = 168; update to the previously published data sets),\textsuperscript{14,15} and a distinct data set of patients from STARTRK-2 who had previously received crizotinib, had CNS-only progression and did not discontinue crizotinib because of non-CNS disease progression or toxicity (N = 18; herein referred to as the post-crizotinib cohort). These are the first data to be reported for the post-crizotinib cohort. Patients with extracranial progression on previous crizotinib treatment were not enrolled in STARTRK-2, as these patients may potentially have mutations that also confer resistance against entrectinib.

All the studies included in this analysis were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. Written informed consent was obtained from all patients. Protocols for all studies were approved by relevant institutional review boards and ethics committees.

Treatment and Assessments

Patients received oral entrectinib 600 mg/d until documented radiographic disease progression (PD), unacceptable toxicity, or withdrawal of consent. Treatment
could continue at the investigator’s discretion when there was evidence of clinical benefit despite radiographic PD. Computed tomography or magnetic resonance imaging scans were performed at screening, end-of-cycle 1 (4 weeks), and every 8 weeks thereafter and assessed by BICR using RECIST version 1.1. Patients with baseline CNS metastases (investigator-assessed) underwent brain scans at every tumor assessment. For patients without baseline CNS metastases, brain scans were only conducted when clinically indicated or when scans were routinely offered in clinical practice.

Safety was assessed by physical examination, laboratory tests, and adverse event (AE) monitoring. AEs were coded using the Medical Dictionary for Regulatory Activities (version 14.0 or higher for individual studies; version 21.0 for integrated safety analysis) and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). Dose reductions could occur in decrements of 200 mg, as needed, with no more than two reductions allowed.

Outcomes

The co-primary end points were confirmed ORR (i.e., proportion of confirmed complete and partial responders [CR and PR, respectively]) and DoR (measured from the date of first objective response to first documented radiographic PD or death by any cause), both assessed by BICR. Key secondary end points were PFS by BICR (i.e., time from the first dose to first documented radiographic PD or death from any cause), OS (i.e., time from the first dose to death from any cause), and safety.

Additional prespecified secondary end points included intracranial ORR (by RECIST version 1.1), intracranial DoR, and intracranial PFS, in patients with baseline BICR-assessed CNS metastases. Intracranial responses and progression were specifically assessed on CNS lesions. Per RECIST version 1.1, non-measurable CNS disease could only be categorized as CR, non-CR/non-PR, or PD. Time to CNS progression by BICR (deaths censored; only radiologically confirmed CNS progression counted as an event) was an exploratory end point, assessed in all patients and patients with or without investigator-assessed baseline CNS metastases.

Molecular Analysis of Resistance Mutations

Genomic analyses before and after entrectinib treatment were carried out using blood samples for circulating tumor DNA analyses to identify potential mechanisms of resistance in the post-crizotinib cohort. The analyses were carried out at Foundation Medicine (Cambridge, MA) using the FoundationOne Liquid CDx assay.19

Statistical Analyses

The efficacy-assessable population comprised all patients with ROS1 fusion–positive NSCLC who had received at least 1 dose of entrectinib, had measurable disease at baseline, and had at least 12 months of follow-up from first posttreatment initiation tumor assessment (or scan). Patients in the post-crizotinib cohort had experienced CNS-only progression on crizotinib before enrolling in STARTRK-2. The safety-assessable population comprised all patients who had received at least 1 dose of entrectinib.

For response data, the number, percentage, and corresponding two-sided 95% Clopper-Pearson exact CIs were summarized. The Kaplan-Meier method was used to estimate time-to-event end points with corresponding 95% CIs. A competing risk analysis of CNS progression, with non-CNS progression and death as competing events, was carried out and cumulative incidence functions were estimated for each of these events.

Analysis of the post-crizotinib cohort was exploratory and used the same methods as the efficacy-assessable population. Patients were enrolled in this cohort under a two-stage sequential testing design. Up to 13 patients were to be enrolled sequentially in the first stage; this stage would be deemed successful on the fourth responder, and enrollment would continue to the second stage, otherwise, enrollment would be stopped.

All statistical analyses were performed using Statistical Analysis System software (v9.3 or higher; SAS Institute Inc., Cary, NC).

Results

Entrectinib in ROS1 TKI-Naïve Patients

Baseline Demographics and Disease Characteristics.

The integrated efficacy-assessable population comprised 168 patients (Supplementary Fig. 1) and the median survival follow-up was 29.1 months (interquartile range [IQR]: 21.8–35.9). The baseline demographics and disease characteristics of the efficacy-assessable population are summarized in Supplementary Table 1. Overall, 63% (n = 105) of patients had received at least 1 previous line of treatment in the metastatic setting. Baseline CNS metastases (investigator-assessed) were present in 58 patients (35%) and confirmed by BICR in 48 patients. There were 27 patients (47%) with CNS metastases (by investigator) who received previous brain radiotherapy. Information on the type of radiotherapy received was available for 18 patients: 12 had whole-brain irradiation and six had stereotactic radiotherapy only. Thirteen different ROS1 fusion partners were identified, the most frequent of which was CD74 (n = 72; 43%) (Supplementary Table 1).
Overall Efficacy With Entrectinib. In the efficacy-assessable population, the ORR was 68% (n/N = 114/168; 95% CI: 60.2–74.8), comprising 22 patients (13%) with a CR and 92 (55%) with a PR (Table 1). The ORR by fusion partner is detailed in Supplementary Table 2. The ORR associated with a 12-month DoR of at least 12 months (Table 1 and Supplementary Fig. 3). The median PFS was 15.7 months (95% CI: 12.0–21.1; 12-month PFS rate 57%) in the overall population (Fig. 1B), 11.8 months (95% CI: 7.7–15.5) in patients with investigator-assessed baseline CNS metastases and 21.1 months (95% CI: 15.1–36.6) in those without (Table 1). There were 54 patients (32%) who died during follow-up. The OS data are immature, with a median OS of 47.8 months (95% CI: 44.1–not estimable) and a 12-month OS rate of 81% (Table 1 and Fig. 1C).

Intracranial Efficacy With Entrectinib. Overall, 48 patients had baseline CNS metastases by BICR, of whom 25 had the measurable disease (Table 2). In patients

Table 1. Overall Efficacy in Patients With ROS1 Fusion-Positive NSCLC Who Were ROS1 TKI-Naive, With or Without CNS Metastases at Baseline, by Investigator

| Efficacy Parameter                  | Efficacy-assessable Population (N = 168) | Baseline CNS Metastasesa (n = 58) | No Baseline CNS Metastasesa (n = 110) |
|------------------------------------|------------------------------------------|----------------------------------|---------------------------------------|
| Objective response, n (%), 95% CI |                                           |                                  |                                       |
| Best overall response, n (%)       | 114 (67.9, 60.2-74.8)                    | 37 (63.8, 50.1-76.0)             | 77 (70.0, 60.5-78.4)                 |
| CR                                 | 22 (13.1)                                | 5 (8.6)                          | 17 (15.5)                            |
| PR                                 | 92 (54.8)                                | 32 (55.2)                        | 60 (54.5)                            |
| Stable disease                     | 15 (8.9)                                 | 5 (8.6)                          | 10 (9.1)                             |
| PD                                 | 14 (8.3)                                 | 8 (13.8)                         | 6 (5.5)                              |
| Non-CR/non-PD                      | 11 (6.5)                                 | 2 (3.4)                          | 9 (8.2)                              |
| Missing or not assessableb         | 14 (8.3)                                 | 6 (10.3)                         | 8 (7.3)                              |
| Duration of response               |                                          |                                  |                                       |
| Median, mo (95% CI)                | 20.5 (14.8-34.8)                         | 14.9 (11.0-20.5)                 | 34.8 (14.9-39.2)                     |
| Range, mo                          | 2.2-55.2c                                | 2.2-42.3c                        | 2.8-55.2c                            |
| Patients with event, n (%)         | 64 (56.1)                                | 23 (62.2)                        | 41 (53.2)                            |
| 12-mo event-free probability, % (95% CI) | 65 (56-74)                           | 62 (45-78)                       | 67 (56-77)                           |
| 18-mo event-free probability, % (95% CI) | 53 (44-63)                           | 44 (27-62)                       | 57 (45-68)                           |
| 24-mo event-free probability, % (95% CI) | 48 (38-58)                           | 31 (14-49)                       | 55 (43-66)                           |
| 36-mo event-free probability, % (95% CI) | 34 (22-46)                           | 17 (0-34)                        | 42 (27-57)                           |
| Overall survival                   |                                          |                                  |                                       |
| Median, mo (95% CI)                | 47.8 (44.1-NE)                           | 28.3 (18.2-NE)                   | NE (44.1-NE)                         |
| Patients with event, n (%)         | 54 (32.1)                                | 26 (44.8)                        | 28 (25.5)                            |
| 12-mo event-free probability, % (95% CI) | 81 (75-88)                           | 75 (63-87)                       | 85 (78-92)                           |
| 18-mo event-free probability, % (95% CI) | 74 (67-81)                           | 64 (50-77)                       | 79 (72-87)                           |
| 24-mo event-free probability, % (95% CI) | 71 (63-78)                           | 59 (45-73)                       | 76 (68-85)                           |
| 36-mo event-free probability, % (95% CI) | 61 (52-70)                           | 43 (27-59)                       | 71 (61-81)                           |

Note: Objective response rate, duration of response, and progression-free survival by BICR (RECIST version 1.1).

aCNS disease at baseline as judged by the investigator.
bMissing or not assessable included patients with no postbaseline scans available, missing subsets of scans, or patients who discontinued before obtaining adequate scans to assess or confirm response.
cCensored.

BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; NE, not estimable; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.
with measurable baseline CNS metastases, the intracranial ORR was 80% (n = 20; 95% CI: 59.3–93.2) (Table 2 and Fig. 1D), including three intracranial CRs. Intracranial responses were durable, with a median DoR of 12.9
months in all patients with baseline CNS metastases and in the subset of patients with measurable disease (Table 2). The intracranial ORR in patients who had not received previous brain radiotherapy or had brain radiotherapy 6 months or longer before starting entrectinib was 48% (n = 13; 95% CI: 28.7–68.1; all patients with measurable and non-measurable baseline CNS disease, by BICR). In patients who had received previous brain radiotherapy shorter than 6 months before starting entrectinib, the intracranial ORR was 57% (n = 12; 95% CI: 34.0–78.2) (Supplementary Table 3).

In all patients with baseline CNS metastases (measurable and non-measurable), the median intracranial PFS, which counts both CNS progression and death as events, was 8.4 months (95% CI: 6.4–13.8); 12-month intracranial PFS rate was 44% (Table 2). In total, 38 (79%) patients had experienced an intracranial PFS event by data cutoff: 28 patients had PD and 10 patients died.

The time to CNS progression (deaths censored) was not estimable in the overall population and 13.6 months (95% CI: 6.7–19.3) in patients with investigator-assessed baseline CNS metastases (n = 58) (Fig. 1E).

Of the 110 patients without baseline CNS metastases, five reported new lesions (4.5%).

On the basis of a competing risks analysis, the risk of having CNS progression on entrectinib, without previous extracranial PD or death, at 12 months, was 39% in patients with investigator-assessed baseline CNS metastases, and 1.0% in those without (Supplementary Table 4). In this study, CNS PD did not necessarily equate to overall PD, depending on the target lesions.

Entrectinib in Patients With CNS-Only Progression After Crizotinib

Baseline Demographics and Disease Characteristics. In total, 18 patients with CNS-only progression (by investigator) on crizotinib were included in the post-crizotinib cohort; recruitment to this cohort was stopped after the first stage of enrollment because of futility. Measurable CNS disease was not a requirement for inclusion in this cohort. Crizotinib could have been received at any previous line of treatment: 16 patients (89%) received crizotinib in the metastatic setting and two (11%) in the neoadjuvant or adjuvant setting. Fifteen patients (83%) received crizotinib

| Table 2. Intracranial Efficacy in Patients With ROS1 Fusion-Positive NSCLC Who Were ROS1 TKI-Naive and Had CNS Metastases at Baseline by BICR |
|-----------------------------------------------|
| Efficacy Parameter                           | All Patients (Measurable and Non-measurable Disease) (n = 48) | Measurable Disease (n = 25) |
| Objective response, n (%), 95% CI            | 25 (52.1, 37.2–66.7) | 20 (80.0, 59.3–93.2) |
| Best overall response, n (%)                 | CR: 8 (16.7) | 3 (12.0) |
|                                               | PR: 17 (35.4) | 17 (68.0) |
| Stable disease                                | 0 | 0 |
| PD                                            | 5 (10.4) | 2 (8.0) |
| Non-CR/non-PD                                 | 14 (29.2) | 0 |
| Missing or not assessablec                   | 4 (8.3) | 3 (12.0) |
| Duration of response                          | Median, mo (95% CI) | 12.9 (7.1–22.1) | 12.9 (6.8–22.1) |
| Range                                         | 1.8–27.6d | 1.8–25.4 |
| Patients with event, n (%)                   | 17 (68.0) | 14 (70.0) |
| 12-mo event-free probability, % (95% CI)     | 52 (32.3) | 50 (27.7–73) |
| 18-mo event-free probability, % (95% CI)     | 34 (15.54) | 33 (10.55) |
| 24-mo event-free probability, % (95% CI)     | 26 (5.46) | 22 (0.44) |
| Progression-free survival                     | Median, mo (95% CI) | 8.4 (6.4–13.8) | 8.8 (6.2–19.3) |
| Patients with event, n (%)                   | 38 (79.2) | 18 (72.0) |
| 12-mo event-free probability, % (95% CI)     | 44 (29.59) | 41 (21.62) |
| 18-mo event-free probability, % (95% CI)     | 25 (12.38) | 32 (12.51) |
| 24-mo event-free probability, % (95% CI)     | 20 (7.32) | 26 (7.45) |

CNS disease at baseline as judged by BICR (RECIST v1.1).

As per RECIST v1.1, non-measurable CNS disease could only be categorized as CR, non-CR/non-PD, or PD.

Missing or not assessable included patients with no postbaseline scans available, missing subsets of scans, or patients who discontinued before obtaining adequate scans to assess or confirm response.

Censored.

BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.
immediately before entrectinib, and three patients (17%) received it in other previous lines or settings. The baseline characteristics of patients in the post-crizotinib cohort are summarized in Supplementary Table 5. All patients had an ECOG PS of 0 (n = 10, 56%) or 1 (n = 8, 44%), and 50% (n = 9) of patients had received more than 2 previous lines of treatment in the metastatic setting. The median duration of previous crizotinib treatment was 12.4 months (range: 2.5–49.0 months). In total, 11 patients (61%) had a PR and four patients (22%) had stable disease as their best overall response to previous crizotinib treatment. Genomic analyses before entrectinib treatment (data from 15 patients) revealed a nonsense ROS1 mutation of unknown significance in one patient. No additional mutations were identified post-entrectinib (data were obtained from 11 patients).

Overall Efficacy After CNS-Only Progression on Crizotinib. Two patients (11%) in the post-crizotinib cohort achieved a PR with entrectinib and there were no CRs (Table 3 and Fig. 2A). The two patients with a PR had a DoR of 7.4 and 29.3 months (Supplementary Fig. 4). There were 4 patients (22%) who had stable disease and all four experienced a decrease in tumor size with entrectinib treatment (Fig. 2A). The median PFS was 4.7 months (95% CI: 2.9–43.5) (Table 3 and Fig. 2B). The OS data remain immature, with seven deaths (39%) reported during follow-up (Table 3 and Fig. 2C). However, we do not expect these data to mature further as some patients have left the study and withdrawn consent. The 12-month OS rate was 69% (95% CI: 46–92).

Intracranial Efficacy. Intracranial efficacy end points were assessed in patients with baseline CNS metastases by BICR (16 of 18 patients in the post-crizotinib cohort). Three patients (19%) had an intracranial response (two CRs and one PR); the intracranial DoR ranged from 7.4 to 23.9 months. In the subgroup of seven patients with measurable baseline CNS disease, one (14%) had an intracranial response (a PR). The median intracranial PFS was 4.5 months (95% CI: 2.9–10.5; n = 16 patients with baseline CNS metastases by BICR) (Table 3), and the median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B). The median time to CNS progression (death censored) was 4.5 months (95% CI: 2.9–43.5) (Fig. 2B).
CI: 2.9–11.9; n = 18 patients with CNS metastases by investigator) (Fig. 2D).

Safety

In total, 224 patients were included in the overall ROS1 fusion–positive NSCLC safety-assessable population. The median time to onset of the first increased creatinine was 8.3 months (95% CI: 4.5–11.7). On the other hand, first neurologic toxicity was experienced early on in this population, with the median time to onset of 0.26 months (95% CI: 0.26–0.33). The most frequent neurologic TRAEs were dysgeusia (41%), dizziness (37%), and paresthesia (18%), and most were grade 1 to 2 (Supplementary Table 6). Two patients experienced one neurologic TRAE each that led to treatment discontinuation (limbic encephalitis and myoclonus).

The time from onset to the time of resolution for AEs of interest is detailed in Table 4. Liver dysfunction and hematological events were short-lived, resolving in less than 1 month on average, whereas eye disorders lasted for longer than 8 months. On average, neurologic toxicities lasted for 4.3 months.

There were 12 patients (5%) in the overall ROS1 fusion–positive NSCLC safety-assessable population who discontinued entrectinib because of TRAEs. The most common TRAEs leading to discontinuation were cardiac...
disorders (n = 4; 2%). There were 82 patients (37%) who had a dose interruption and 75 patients (34%) who had a dose reduction because of TRAEs. The median dose intensity over the duration of the study was 91% (IQR: 66.7–99.5).

**Discussion**

We report updated efficacy and safety data from an integrated analysis of three entrectinib trials in patients with *ROS1* fusion–positive NSCLC, with an expanded population and longer follow-up compared with the previous analysis. With a median survival follow-up of 29.1 months, almost double the previous length of follow-up, responses were more durable than in the previous analysis (median DoR: 20.5 versus 15.7 mo, respectively). These more mature data reinforce those from the earlier data-cuts, and provide new observations. For example, more patients achieved a CR (13% versus 8.7%, respectively), suggesting that responses continued to deepen over time. Most importantly, we provide the first estimate of the median OS with entrectinib in patients with *ROS1* TKI–naive *ROS1* fusion–positive NSCLC (47.8 mo, comparable to that with crizotinib [51.4 months]), although these data remain immature (~30% of patients had an event) and longer survival follow-up is needed. Our analysis also includes a cohort of patients who received entrectinib after CNS-only PD post-crizotinib. Whereas derived from a small number of patients, to date these results represent the most comprehensive data set from a clinical study in this subgroup of patients and should be taken into account when making treatment decisions.

The median PFS with entrectinib in our analysis (15.7 mo [95% CI 12.0–21.1]) was comparable to that reported for crizotinib (15.9 mo; N = 127) and ceritinib (19.3 mo; N = 30) and lower than that reported for lorlatinib (21.0 mo; N = 21), repotrectinib (24.6 mo; N = 11) and talrorectinib (29.1 mo; N = 11). However, it should be noted that the number of patients in this entrectinib study was much higher than in the studies of the other TKIs. Generally, cross-trial comparisons should be viewed with caution because of the differences in study populations.

In total, 35% of the *ROS1* TKI–naive patients had investigator-assessed baseline CNS metastases. In these patients who tend to have a poorer prognosis than those without CNS involvement, the ORR was high (64%) and responses were durable (12-mo DoR rate: 62%). More importantly, the intracranial activity observed previously with entrectinib was maintained with the extended follow-up, with an intracranial ORR of 80% and a 12-month intracranial DoR rate of 50% in patients with measurable baseline CNS metastases (overall intracranial ORR: 52%; 12-mo DoR rate: 52%). This was also true for intracranial ORR in patients who had not received previous brain radiotherapy or had received previous brain radiotherapy at least 6 months before entrectinib treatment. As we highlighted previously, this suggests that the intracranial efficacy observed with entrectinib is unlikely confounded by the ongoing effects of brain radiotherapy. Of note, only five patients (4.5%) without baseline CNS metastases developed new brain lesions. Although brain scans were not mandated for these patients, these data suggest a role for entrectinib in delaying or preventing the development of brain metastases, even in patients without baseline CNS disease. More data would be needed to make any definitive conclusions.

The intracranial benefit seen with entrectinib is of clinical relevance, given that approximately 40% of patients with *ROS1* fusion–positive NSCLC will have CNS metastases at diagnosis. As noted previously, evidence of intracranial efficacy with other *ROS1* TKIs remains limited because of small sample sizes with ORRs of 25% (2 out of 8 patients) for ceritinib, 64% (7 out of 11 patients) for lorlatinib and not reported for crizotinib, recognizing the caveats of cross-trial comparisons. No head-to-head trials have yet been conducted, although a randomized, open-label, phase 3 trial of entrectinib versus crizotinib in patients with *ROS1* fusion–positive NSCLC (NCT04603807) has recently started recruiting.
For the first time, we also report data from a retrospective, exploratory analysis of entrectinib in patients with ROS1 fusion–positive NSCLC who had CNS-only progression on crizotinib before entering the STARTTRK-2 trial. We included this cohort of patients to determine the efficacy of entrectinib after the presumed pharmacologic failure of crizotinib in the CNS. Baseline characteristics for this post-crizotinib cohort were generally similar to those of the ROS1 TKI-naïve population, with a few notable differences. Patients in the post-crizotinib cohort were overall more fit (none had ECOG PS 2, versus 10% of patients in the ROS1 TKI-naïve population) albeit more heavily pretreated (17% versus 8% of patients had received at least 4 previous lines of systemic therapy in the metastatic setting, respectively).

Both the systemic and the intracranial efficacy of entrectinib were modest in the post-crizotinib cohort compared with the ROS1 TKI-naïve cohort. This may reflect the development of cross-TKI resistance mechanisms in the CNS after previous crizotinib treatment, in addition to heavy pretreatment possibly increasing overall genomic complexity. Notably, lorlatinib also yielded a low ORR (35%) and short median PFS (8.5 months) in crizotinib-refractory patients with ROS1 fusion–positive NSCLC.22 Unlike its activity in ALK fusion–positive lung cancers, lorlatinib is unable to target recalcitrant resistance mutations in ROS1, such as those involving the solvent front.2 Acquired resistance to TKIs is still not fully understood. In an analysis of TKI-naïve patients from the STARTTRK-2 study (data cutoff: May 2018), 26% (n = 5 out of 19) of patients had detectable acquired mutations in ROS1 (ROS1G2032R; ROS1P2004E/C) at PD after treatment with entrectinib.27 Although no known ROS1-acquired resistance mutations were identified in our study (analysis in the post-crizotinib cohort), other still unidentified mechanisms, such as epigenetic changes, may be involved. In addition, our molecular analysis was carried out on circulating tumor DNA, which may have limitations compared with the sequencing of tumor tissue.

Finally, the safety profile of entrectinib in this updated analysis was consistent with that of the previous two analyses.14,17 We observed an early onset of neurologic adverse effects that resolved in many patients within approximately 4 months. These were not unexpected given that entrectinib is a potent inhibitor of TRKA, TRKB, and TRKC, which maintain important neurologic roles in adults, including the regulation of balance, appetite (the most common grade 3 TRAE in this data set was weight gain) and pain thresholds.28 A late onset of increased creatinine, which resolved within approximately 2 months, was also observed, consistent with the role of entrectinib as a MATE1 inhibitor in the kidney.29 The inhibition of MATE1 can result in the false estimation of true kidney health if creatinine alone is used to calculate the glomerular filtration rate. As such, a patient’s renal function may seem artificially impaired. Measuring the glomerular filtration rate by means of cystatin-C can provide a better estimate.29

Limitations of this study include the relatively small sample size, the single-arm study design, and the lack of mandatory requirements for post-progression tissue collection.

Investigating the effect of entrectinib after CNS-only progression on crizotinib is relevant for clinical practice. The NCCN guidelines recommend crizotinib or entrectinib as preferred first-line TKIs, whereas lorlatinib is only recommended for use after progression on previous TKI treatment.16 After a recent update, the guidelines now also recommend entrectinib as second-line therapy after progression on crizotinib, particularly for patients with CNS metastases.16 Although there is some evidence of intracranial efficacy in the post-crizotinib cohort in this study, patients who receive entrectinib for CNS PD should be monitored carefully, preferably with an early scan, given the overall modest outcomes and low likelihood of response observed in this analysis.

In conclusion, entrectinib exhibited substantial systemic and intracranial efficacy in ROS1 TKI-naïve patients with ROS1 fusion–positive NSCLC. The overall efficacy and intracranial efficacy seen with entrectinib when patients have had CNS progression on previous crizotinib treatment was modest. On the basis of these data, physicians should carefully consider the most appropriate TKI treatment sequence for individual patients. To ensure maximal efficacy, entrectinib should be considered as a first-line treatment for patients with ROS1 fusion–positive NSCLC.

CRediT Authorship Contribution Statement

Alexander Drilon: Investigation, Writing - original draft, Writing - review & editing.
Chao-Hua Chiu; Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G. Krebs, Stephen V. Liu, Thomas John, Gregory A. Otterson, Daniel S. W. Tan, Tejas Patil, Rafal Dziadziouszko, Erminia Massarelli, Takashi Seto, Robert C. Doebele, Salvatore Siena: Investigation, Writing - review & editing.
Bethany Pitcher: Software, Formal analysis, Data curation, Writing - review & editing.
Nino Kurtsikidze: Writing - review & editing.
Sebastian Heinzmann: Data curation and interpretation; Writing - original draft; Writing - review & editing.
Role of the Sponsor
F. Hoffmann-La Roche Ltd was involved in the design of the study; the analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.

Data Availability Statement
For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli (https://vivli.org/ourmember/roche/). For up-to-date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked because of a potential increase in the risk of patient re-identification.

Acknowledgments
This study was supported by F. Hoffmann-La Roche Ltd. The authors thank the patients, their families, and the participating study centers. Dr. Krebs acknowledges support from National Institute for Health Research (NIHR) Manchester Biomedical Research Centre and NIHR Manchester Clinical Research Facility at The Christie and Manchester Experimental Cancer Medicine Centre (Manchester, United Kingdom). The analysis of resistance mutations was carried out by Timothy Wilson, PhD, of Genentech, Inc., San Francisco, California. Statistical analysis support was provided by Vanessa Grassi of Cytel Inc., France. Help with data requests was provided by Laura Verzog, PhD, of Ashfield MedComms, an Ashfield Health company. Sunil Sharma, MPH, of Syneos Health, provided support in curating the data. The authors also thank Dr. Marwan Fakhil of City of Hope Comprehensive Cancer Center, Duarte, California for his review of the outline of this article. Third-party medical writing assistance, under the direction of the authors, was provided by Lietta Nicolaides, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by F. Hoffmann-La Roche Ltd.

Supplementary Data
Note: To access the supplementary material accompanying this article, visit the online version of the JTO Clinical and Research Reports at www.jtocrr.org and at https://doi.org/10.1016/j.jtocrr.2022.100332.

References
1. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19:4040-4045.
2. Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2020;18:35-55.
3. Bergethon K, Shaw AT, Ou S-HI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.
4. Dugay F, Llamas-Gutierrez F, Gournay M, et al. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in Caucasian patients: data from a cohort of 713 nonsquamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. Oncotarget. 2017;8:53336-53351.
5. Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis Oncol. 2017;2017.
6. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EURO51 cohort. J Clin Oncol. 2015;33:992-999.
7. Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13:1717-1726.
8. Wu YL, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:1405-1411.
9. US Food and Drug Administration. XALKORI Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf. Accessed February 7, 2022.
10. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443-e445.
11. Fischer H, Ullah M, de la Cruz CC, et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-Oncology. 2020;22:819-829.
12. Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15:628-639.
13. Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: A new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRK)s Inhibitor. J Med Chem. 2016;59:3392-3408.
14. Drilon A, Siena S, Dziadziszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:261-270.
15. Dziadziszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer. J Clin Oncol. 2021;39:1253-1263.
16. National Comprehensive Cancer Network. Non-small cell lung cancer. version 1.2022. https://www.nccn.
17. Doebele R, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271-282.

18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. 1.1 version. Eur J Cancer. 2009;45:228-247.

19. Foundation Medicine. Inc. FoundationOne® LiquidCDx. https://www.foundationmedicine.com/test/foundationone-liquid-cdx. Accessed February 7, 2022.

20. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30:1121-1126.

21. Lim SM, Kim HJ, Lee J-S, et al. Open-Label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35:2613-2618.

22. Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2019;20:1691-1701.

23. Cho BC, Doebele RC, Lin J, et al. Phase 1/2 TRIDENT-1 study of repotrectinib in patients with ROS1+ or NTRK+ advanced solid tumors. J Thorac Oncol. 2021;16(suppl):S174-S175.

24. Ou SI, Fujiwara Y, Shaw AT, et al. Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: an updated pooled analysis of U.S. and Japan Phase 1 studies. JTO Clin res rep. 2021;2:100108.

25. Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer. 2001;32:129-136.

26. ClinicalTrials.gov. NCT04603807. https://clinicaltrials.gov/ct2/show/NCT04603807. Accessed February 7, 2022.

27. Dziadziuszko R, Hung T, Wang K, et al. Pre and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumors treated with entrectinib [e-pub ahead of print]. Mol Oncol. 2022;10.1002/1878-0261.13214. Accessed May 23, 2022.

28. Liu D, Flory J, Lin A, et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020;31:1207-1215.

29. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30:viii23-viii30.